{
    "code": "02022551",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02022551",
    "time": "2022-10-28 05:50:33",
    "許可證字號": "衛署藥輸字第022551號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "113\/07\/26",
    "發證日期": "88\/07\/26",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原登錄字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA00202255100",
    "中文品名": "安普諾維膜衣錠１５０毫克",
    "英文品名": "APROVEL 150MG FILM-COATED TABLETS",
    "適應症": "本態性高血壓之治療。治療併有高血壓及第二型糖尿病患者的高血壓及糖尿病性腎病變。",
    "劑型": "116膜衣錠",
    "包裝": "鋁箔盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "IRBESARTAN",
    "限制項目": "02輸　入 52依本署七七公告於國內進行臨床試驗且核定為新藥",
    "申請商名稱": "1424601100  賽諾菲股份有限公司",
    "申請商地址": "台北市信義區松仁路3號7樓",
    "主製造廠": [
        {
            "製造廠名稱": "FFR0141000  SANOFI WINTHROP INDUSTRIE",
            "製造廠廠址": "30-36 AVENUE GUSTAVE EIFFEL 37100 TOURS FRANCE",
            "製造廠公司地址": "",
            "製造廠國別": "FRANCE",
            "製程": ""
        }
    ],
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200038400",
            "成分名稱": "IRBESARTAN",
            "含量描述": "",
            "含量": "150.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "白色",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "橢圓形",
        "標記一": "2772",
        "標記二": "賽諾菲聖德拉堡1"
    },
    "藥物辨識外觀圖片": [
        {
            "title": "02022551.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022551&Seq=435&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "721851_Aprovel 150& 300mg_leaflet_CCDSv17_2021-10-15-111-04-13(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022551&Seq=007&Type=9"
        },
        {
            "title": "02 Aprovel_LPI_C_CCDS v17_TFDA comment_clean-110-03-29.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022551&Seq=006&Type=9"
        },
        {
            "title": "721849_Aprovel 150mg_box_2021-10-15-111-04-13(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022551&Seq=012&Type=8"
        },
        {
            "title": "Aprovel 150mg_box & tab-104-09-03(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02022551&Seq=011&Type=8"
        }
    ]
}